Health Care · Surgical & Medical Instruments & Apparatus · Nasdaq · CIK 1778922 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $21.91Day +1.34%Mkt cap $733MOff 52W high −32.5%Vol (1Y) 72.0%
Daily closing price, split-adjusted to the current basis; 0.4y shown of 109 bars on file. Sampled to 109 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest3.4% of sh out |
| Days to cover7.9d |
| Top-10 13F concentration92.4% |
| Next report (est.)2026-08-20 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$39.9M |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
No return windows available for SGP.
| Ann. volatility (1Y)72.0% |
| Ann. volatility (3Y)72.0% |
| Sharpe (1Y)−0.24 |
| Sharpe (3Y)−0.24 |
| Max drawdown (1Y)−40.8% |
| Max drawdown (3Y)−40.8% |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 8.0M | $208M | 23.99% | new |
| NEA Management Company, LLC | 7.4M | $192M | 22.11% | new |
| Sands Capital Alternatives, LLC | 2.5M | $65M | 7.48% | new |
| SAMSARA BIOCAPITAL, LLC | 2.1M | $55M | 6.31% | new |
| PRICE T ROWE ASSOCIATES INC /MD/ | 704,440 | $18M | 2.11% | new |
| Vestal Point Capital, LP | 666,760 | $17M | 1.99% | new |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 550,000 | $14M | 1.65% | new |
| JPMORGAN CHASE & CO | 577,109 | $13M | 1.73% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | −$0.69 | — | — | — |
| 2025-03-31 | — | −$3.96 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-20 is ESTIMATED from filing cadence (median gap 49d) — not company-confirmed.
